Adamo Daniela, Coppola Noemi, Pecoraro Giuseppe, Nicolò Michele, Mignogna Michele Davide
Department of Neurosciences, Reproductive and Odontostomatological Sciences, University Federico II of Naples, Naples, Italy.
Cranio. 2023 Mar;41(2):126-130. doi: 10.1080/08869634.2020.1804233. Epub 2020 Aug 10.
The treatment of trigeminal neuralgia (TN) involves first- and second-generation anticonvulsants. However, side effects (SEs) impair compliance with treatment, especially in elderly patients. Lacosamide (LCM) is a third-generation anticonvulsant with a mechanism of action that is not completely clear. It has few SEs and has been considered in the treatment of neuropathic pain.
LCM was prescribed as a monotherapy for a 60-year-old female with TN who had proven refractory to previous treatments in terms of both the absence of any pain relief and the appearance of severe leukopenia. The treatment dosage was 100 mg twice daily. Pain relief was obtained after three weeks of treatment without any SEs. Currently, the patient takes a maintenance dosage of 100 mg/daily, remaining in a state of complete well-being.
LCM has shown evidence of a potential efficacy and a good safety profile in the treatment of this patient with TN.
三叉神经痛（TN）的治疗涉及第一代和第二代抗惊厥药。然而，副作用会影响治疗依从性，尤其是在老年患者中。拉科酰胺（LCM）是一种第三代抗惊厥药，其作用机制尚不完全清楚。它的副作用较少，已被用于治疗神经性疼痛。
一名60岁患有TN的女性患者，之前的治疗均无效，且出现了严重的白细胞减少症，现采用LCM单药治疗。治疗剂量为每日两次，每次100毫克。治疗三周后疼痛缓解，且无任何副作用。目前，患者维持剂量为每日100毫克，状态良好。
LCM在该TN患者的治疗中显示出潜在疗效和良好的安全性。
